United Kingdom Montelukast Intermediate Market Size & Outlook, 2026-2034
United Kingdom Montelukast Intermediate Market Insights
- As highlighted in Reed Intelligence analysis, the United Kingdom Montelukast Intermediate Market, worth USD 0.32 Million in 2025, is forecasted to achieve USD 0.48 Million by 2034.
- The United Kingdom market is anticipated to grow at a CAGR of 4.66% during the period 2026–2034.
- By 2025, GMP represented the largest share of the By Type market size.
- Non-GMP is expected to remain the key growth driver within By Type, registering the fastest CAGR during the forecast period.
![United Kingdom Montelukast Intermediate Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/united-kingdom-montelukast-intermediate-market-united-kingdom-by-type-237353.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United Kingdom represented 4.04% of the overall global Montelukast Intermediate Market size.
- United States is projected to lead the global Montelukast Intermediate Market size by 2034.
- Across Europe, Germany is anticipated to hold the dominant position in market size by 2034.
- Russia is forecasted to expand at the fastest pace in Europe, attaining USD 0.21 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 0.32 Million |
| Market Size In 2034 | USD 0.48 Million |
| Largest segment | GMP |
| Units | Revenue in USD Million |
| CAGR | 4.66% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Applications |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Kingdom Montelukast Intermediate Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMP | XX.x | XX.x | XX.x | 0.2 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-GMP | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Montelukast Intermediate Market By Applications 2026-2034 (USD Million)
| By Applications | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asthma | XX.x | XX.x | XX.x | 0.13 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bronchospasm | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Allergic Rhinitis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Urticaria | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Montelukast Intermediate Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Biotechnological Companies | XX.x | XX.x | XX.x | 0.14 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.